vs
Side-by-side financial comparison of LINKBANCORP, Inc. (LNKB) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $46.0M, roughly 1.5× LINKBANCORP, Inc.). LINKBANCORP, Inc. runs the higher net margin — 6.4% vs -49.0%, a 55.4% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 7.3%). LINKBANCORP, Inc. produced more free cash flow last quarter ($23.8M vs $-84.7M).
LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
LNKB vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.0M | $70.6M |
| Net Profit | $2.9M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 8.5% | -56.7% |
| Net Margin | 6.4% | -49.0% |
| Revenue YoY | 7.3% | 81958.1% |
| Net Profit YoY | -61.2% | 54.9% |
| EPS (diluted) | $0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $46.0M | — | ||
| Q3 25 | $44.8M | $70.6M | ||
| Q2 25 | $42.3M | — | ||
| Q1 25 | $53.4M | — | ||
| Q4 24 | $42.9M | — | ||
| Q3 24 | $42.9M | — | ||
| Q2 24 | $41.3M | — | ||
| Q1 24 | $40.5M | — |
| Q4 25 | $2.9M | — | ||
| Q3 25 | $7.8M | $-34.6M | ||
| Q2 25 | $7.4M | — | ||
| Q1 25 | $15.3M | — | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $7.1M | — | ||
| Q2 24 | $5.8M | — | ||
| Q1 24 | $5.7M | — |
| Q4 25 | 8.5% | — | ||
| Q3 25 | 22.3% | -56.7% | ||
| Q2 25 | 22.4% | — | ||
| Q1 25 | 36.0% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 21.3% | — | ||
| Q2 24 | 18.0% | — | ||
| Q1 24 | 18.1% | — |
| Q4 25 | 6.4% | — | ||
| Q3 25 | 17.5% | -49.0% | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 28.7% | — | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | 16.5% | — | ||
| Q2 24 | 14.1% | — | ||
| Q1 24 | 14.1% | — |
| Q4 25 | $0.08 | — | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.20 | — | ||
| Q1 25 | $0.41 | — | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $0.19 | — | ||
| Q2 24 | $0.16 | — | ||
| Q1 24 | $0.15 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.3M | $490.9M |
| Total DebtLower is stronger | $177.3M | — |
| Stockholders' EquityBook value | $306.4M | $503.0M |
| Total Assets | $3.1B | $577.1M |
| Debt / EquityLower = less leverage | 0.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.3M | — | ||
| Q3 25 | $194.2M | $490.9M | ||
| Q2 25 | $155.1M | — | ||
| Q1 25 | $220.2M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $191.2M | — | ||
| Q2 24 | $181.7M | — | ||
| Q1 24 | $172.3M | — |
| Q4 25 | $177.3M | — | ||
| Q3 25 | $102.3M | — | ||
| Q2 25 | $102.3M | — | ||
| Q1 25 | $102.7M | — | ||
| Q4 24 | $112.5M | — | ||
| Q3 24 | $102.4M | — | ||
| Q2 24 | $102.3M | — | ||
| Q1 24 | $102.2M | — |
| Q4 25 | $306.4M | — | ||
| Q3 25 | $305.5M | $503.0M | ||
| Q2 25 | $298.0M | — | ||
| Q1 25 | $294.1M | — | ||
| Q4 24 | $280.2M | — | ||
| Q3 24 | $277.4M | — | ||
| Q2 24 | $271.4M | — | ||
| Q1 24 | $268.2M | — |
| Q4 25 | $3.1B | — | ||
| Q3 25 | $3.1B | $577.1M | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $2.9B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.9B | — | ||
| Q2 24 | $2.9B | — | ||
| Q1 24 | $2.8B | — |
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.33× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.38× | — | ||
| Q1 24 | 0.38× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.3M | $-84.6M |
| Free Cash FlowOCF − Capex | $23.8M | $-84.7M |
| FCF MarginFCF / Revenue | 51.7% | -120.1% |
| Capex IntensityCapex / Revenue | 3.2% | 0.2% |
| Cash ConversionOCF / Net Profit | 8.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.3M | — | ||
| Q3 25 | $23.6M | $-84.6M | ||
| Q2 25 | $6.3M | — | ||
| Q1 25 | $2.6M | — | ||
| Q4 24 | $25.4M | — | ||
| Q3 24 | $14.0M | — | ||
| Q2 24 | $6.4M | — | ||
| Q1 24 | $-771.0K | — |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $23.2M | $-84.7M | ||
| Q2 25 | $6.1M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $22.6M | — | ||
| Q3 24 | $13.1M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-1.2M | — |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 51.8% | -120.1% | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 52.6% | — | ||
| Q3 24 | 30.5% | — | ||
| Q2 24 | 15.3% | — | ||
| Q1 24 | -3.0% | — |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 0.8% | 0.2% | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 8.59× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 3.35× | — | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
